Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors 1,2 , yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using wholeexome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8 + T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted crossreactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.
+ T cells using multiplexed immunohistochemistry. c, d, T-cell frequency and repertoire clonality (c) and clonal overlap (d) in tumour and matched adjacent normal pancreatic tissues, determined by TCR Vβ sequencing. e, Intratumoural T-cell repertoire clonality in tumours of short-and long-term survivors of PDAC. Horizontal bars indicate median values. n is the number of biologically independent samples in individual patients. P values were determined using a log-rank test (a), a two-tailed Mann-Whitney U-test (b), a two-tailed paired (c) and a two-tailed unpaired Student's t-test (e). , and antigen experience (PD-1 and TIGIT) 5 , as well as downregulation of the immunosuppressive marker STAT3 (Extended Data Fig. 2b ). Sequencing of the T-cell receptor (TCR) Vβ chain demonstrated that intratumoural T cells were increased fivefold compared to matched adjacent non-tumour pancreatic tissue and were markedly polyclonal (Fig. 1c) . Notably, more than 94% of intratumoural T-cell clones were unique to tumours, consistent with tumour specificity (Fig. 1d) . Additionally, in unselected patients, flow cytometry on intratumoural T cells revealed activation and memory marker upregulation compared to draining lymph node and blood T cells, consistent with antigen specificity (Extended Data  Fig. 2c ). Finally, tumours of LTSs exhibited greater TCR repertoire diversity (Fig. 1e) . The association of activated CD8 + T cells and survival was independent of clinicopathological factors and adjuvant chemotherapy (Extended Data Fig. 2d ). Collectively, tumours of LTSs exhibited an activated, polyclonal, tumour-specific T-cell infiltrate, suggesting differential antigenic targets.
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To determine the neoantigen frequency in PDACs, we performed whole-exome sequencing on macrodissected tumour islands. We detected a median of 38 predicted neoantigens per tumour 6 (Extended Data Fig. 3a , Supplementary Table 1) . Notably, patients with both the highest predicted neoantigen number and either the greatest CD3 + CD8 + , or polyclonal T-cell repertoire, but neither alone, exhibited the longest survival (median survival not reached, Fig. 2a , Extended Data Fig. 3b ). We corroborated these findings using a second neoantigen prediction algorithm 7 ( Fig. 2a , Extended Data Fig. 3b, c ). This association of higher neoantigen quantity and CD8
+ T-cell infiltrate with survival was independent of adjuvant chemotherapy (Extended Data Fig. 3d ). Furthermore, we found that higher neoantigen quantity and CD8
+ T-cell infiltrate together exhibited the strongest association with survival, with other genomic and immune parameters showing weak or no association with survival 8 (Extended Data Fig. 4a-d) . Together, these data suggest that neoantigen immunogenicity and quality, and not purely quantity, correlate with survival. Next, we investigated neoantigen qualities that modulate differential immunogenicity. The theory of molecular mimicry postulates that TCRs that can recognize pathogenic antigens can also recognize nonpathogenic antigens, which has been documented in autoimmunity 9 but not in the cancer context. We theorized that neoantigen homology to infectious disease-derived epitopes, which are recognized by the human TCR repertoire, can serve as a partial surrogate for differential neoantigen immunogenicity or 'non-selfness' . This hypothesis does not assume any associations between pre-existing antimicrobial immunity and survival, but rather aims to develop a strategy to identify candidate neoantigens based on defined immunogenic pathogen-derived epitopes. To test this hypothesis, we developed neoantigen quality and quantity models (Extended Data Fig. 5a , b). For each neoantigen in the quality model, we derived sequence alignment scores to human infectious disease-derived, class I-restricted peptide sequences with positive immune assays (hereby referred to as 'microbial') from the Immune Epitope Database (IEDB, Supplementary Table 2) . We then inferred its probability of TCR recognition using a nonlinear logistic dependence on alignment score, and calculated quality scores by amplifying these binding probabilities by inferred relative wild-type and mutant peptide-MHC class I affinities (Extended Data Fig. 5a, b) . For the quantity model, the neoantigen score equalled the total number of neoantigens within a clone. Using an evolutionary model, we interpreted the score of a clone as calculated by each model as its fitness cost due to immune interactions 10 . We then recreated the clonal tree structure for each tumour based on mutant allele frequencies, and projected the change to the effective cancer cell population size of each tumour. Of these models, the quality model, but not the quantity model, significantly stratified short-and long-term survivors independent of confounding factors and adjuvant chemotherapy (Fig. 2b, Extended  Data Fig. 6a) . Notably, all tumours with the highest neoantigen load in combination with the most abundant CD8
+ T-cell infiltrates harboured high-quality neoantigens (Extended Data Fig. 3e ). Testing these models by neoantigen quality and quantity in the MSKCC (left) and ICGC (right) cohorts. OS, overall survival. n is the number of biologically independent samples in individual patients. P values were determined using a log-rank test.
Letter reSeArCH 5 in a larger cohort unselected by survival (International Cancer Genome Consortium (ICGC); n = 166), neoantigen quality, but not quantity, was significantly prognostic of survival and independent of confounding variables (Fig. 2b, Extended Data Fig. 6b, c) , with a stable association with survival in subsampled datasets in both cohorts (Extended Data  Fig. 7a, b) . We conclude that neoantigen quality is a biomarker of survival in PDAC.
Recent data have shown that T-cell-recognized neoantigens can be selectively lost from the tumour cell population by either mutant allelic loss or overall reduced gene expression 11 . Consistently, genes with high-quality neoantigens evidenced a modest trend to lower mRNA expression compared to gene expression in the absence of high-quality neoantigens (Fig. 3a) . To explore further possible in vivo high-quality neoantigen immunoediting, we examined neoantigen clonal dynamics n is the number of biologically independent samples in individual patients in a and c. P values were determined using a two-tailed Student's t-test (a), a two-tailed Mann-Whitney U-test (b), a one-way analysis of variance (ANOVA) with Tukey's multiple comparison test (c) and as described in the Methods (d).
on primary-to-metastatic tumour progression in one patient obtained through rapid autopsy. Of the three clones in the primary tumour, both clones with high-quality neoantigens were lost in multiple metastatic samples, in contrast to the clone with a low-quality neoantigen that was propagated to multiple metastatic sites (Fig. 3b, Extended Data Fig. 1f ). These findings suggest differential immune fitness of clones bearing high-versus low-quality neoantigens within the same primary tumour. Next, we sought to detect in vivo T-cell responses to high-quality neoantigens. We identified 7 very long-term survivors of PDAC (median overall survival 10.5 years) that normally account for less than 2% of all patients with PDAC (Extended Data Fig. 1g ), and pulsed their peripheral blood mononuclear cells (PBMCs) with antigens predicted by the quality model. Notably, we observed selective CD8 + T-cell expansion and degranulation (as measured by CD107a expression) to neopeptides and their homologous infectious disease-derived peptides (deemed the 'cross-reactive' peptide relative to a neoantigen) but not to their wild-type peptides (Fig. 3c , Extended Data Fig. 8a , b, Supplementary Table 3) . Moreover, in all patients, identical TCR clones were significantly expanded to both the neopeptides and cross-reactive peptides (Fig. 3d) . In five out of seven patients, we identified neoantigen and microbial cross-reactive peripheral T-cell clones, and in seven out of seven patients high-quality neoantigen-reactive T-cell clones that were also present in their respective archival primary tumours. Patient 3, alive and disease-free 12 years after primary tumour removal, illustrated the most extreme instance-15 neoantigen and microbial cross-reactive T-cell clones that persisted in the peripheral blood were found in the primary tumour, including the most frequent intratumoural T-cell clone with a rank frequency of 6.2% (Fig. 3d) . We conclude that our quality model identifies bona fide neoantigens targeted by T cells, and that tumour-infiltrating T cells can crossreactively recognize both cancer neoantigens and homologous non-cancer microbial antigens.
In exploring whether select genetic loci or 'immunogenic hotspots' were preferentially enriched for neoantigens, we detected four loci harbouring neoantigens in more than 15% of all patients, with one locus preferentially enriched in LTSs: the tumour antigen MUC16, which is a common ovarian cancer biomarker and an established T-cell immunotherapy target 12 ( Fig. 4a) . In tumours of LTSs, we found a fourfold higher frequency of MUC16 neoantigens and several MUC16 neoantigens in the same tumour, whereas non-antigenic MUC16 mutation frequency was no different (Fig. 4b, c, Extended Data Fig. 9a ). Only one patient with MUC16 neoantigens had a hypermutated phenotype (more than 500 mutations), and exclusion of this patient did not alter the results (Fig. 4c) . Supporting possible in vivo anti-MUC16 immunity, tumours in LTSs had lower levels of mRNA (6.6-fold), protein, and a lower mutant allele frequency (4-fold) in non-hypermutated tumours compared to short-term survivors (Extended Data Fig. 9b) . Consistently, the pVAC-Seq pipeline identified MUC16 as the most common locus generating neoantigens, after the frequently mutated oncogenes (KRAS and TP53) (Extended Data Fig. 9c ). We found no differences between the two cohorts in cell-autonomous regulators of MUC16 expression, mediators of MUC16-dependent effects on tumour progression, other mucin or tumour antigen expression, or evidence of MUC16 mutations altering RNA or protein expression [13] [14] [15] [16] (Extended Data Fig. 9d ). One interpretation of these results is that MUC16 neoantigen-specific T-cell immunity induces immunoediting of MUC16-expressing clones in primary tumours, and prolongs survival, given the cell-autonomous roles of MUC16 in promoting metastases 14, 16 . Notably, MUC16 protein expression was low yet not absent in the tumours of LTSs, indicating antigen availability, and mutations did not affect cell intrinsic expression (Extended Data Figs 9e, 10a-c). Consistent with possible MUC16 immunoediting, MUC16 neoantigens in primary tumours had complete neoantigenic mutational loss in matched metastases (n = 10), in contrast to MUC16 non-neoantigenic mutations that demonstrated mutation enrichment on metastatic progression (Fig. 4d, Extended Data Fig. 1f) . MUC16 was also the only locus recurrently harbouring neoantigens in both MSKCC and ICGC cohorts, outside of the most frequently mutated genes (oncogenes KRAS, TP53; largest human gene TTN) (Extended Data Fig. 9c ). Although the propensity to generate MUC16 neoantigens may be related to its large size, we did not detect trends towards neoantigen formation based on gene size alone across cohorts or pipelines. Additionally, as the number of patients with MUC16 neoantigens in the LTS cohort was small, validation in a larger LTS dataset is warranted. Hence MUC16 is a candidate immunogenic hotspot in PDAC.
We next stimulated peripheral blood from two LTSs (both disease-free 8 years after surgery) with predicted MUC16 neoantigens. In both patients, we observed CD8 + T-cell expansion and degranulation, with expanded clones detected in archival surgically resected primary tumours (Fig. 4e, Extended Data Fig. 9f ). We confirmed peripheral blood CD8
+ T-cell recognition of two additional MUC16 neoantigen-MHC complexes using peptide-MHC multimers in human leukocyte Letter reSeArCH
antigen (HLA)-matched healthy donors (Extended Data Fig. 8c ), consistent with putative MUC16 neoantigen binding by the human TCR repertoire. Hence we present evidence of in vivo T-cell reactivity to neoantigens in the tumour antigen MUC16, with lasting MUC16-specific T-cell immunity in survivors of PDAC.
Our results do not indicate causal associations of pre-existing microbial and anti-tumour immunity in LTSs. Instead, our data suggest that embedding microbial homology in the context of our neoantigen quality model can help to create an effective surrogate for immunogenic neoantigens. We posit two non-mutually exclusive mechanisms to explain these findings. The first is that although the naive human TCR repertoire is theoretically vast, the observed TCR recombination products are notably restricted 17 , possibly representing sculpting of the TCR recombination space under the evolutionary selection pressures of pathogens, thereby skewing the repertoire to recognize their common protein features. The second is that as microbial antigens are by definition non-self sequences, enriched with documented human T-cell clones surviving thymic selection, homologous tumour neo antigens are similarly non-self sequences enriched with bona fide human T-cell clones. However, given recent evidence of intratumoural bacterial polarization of T-cell phenotypes 18 , and microbial dependence of immunotherapy efficacy 9 , whether homology to patient-derived microbiomes enhances relevant neoantigen identification remains unknown yet timely. Notably, we identified no associations with survival when neoantigen quality was calculated using alignment to immunogenic allergy or autoimmune-derived IEDB peptides (Extended Data Fig. 7c ). However, the significant size discrepancy between the number of infectious disease-derived (Supplementary Table 2 ) and allergy or autoimmune-derived (Supplementary Table 4 ) peptides would warrant confirmation of these results in a larger allergy or autoimmune peptide dataset.
Although viral-specific T cells have been detected in human tumours 19 , the presence of identical circulating and intratumoural T-cell clones reactive to both high-quality neoantigens and infectious disease-derived sequences offers proof-of-principle of neoantigenic molecular mimicry in a cancer context. Although patients with high-quality neoantigen tumours exhibited prolonged survival, it remains unproven whether these cross-reactive T-cell clones contribute to this outcome, or whether this reflects the degeneracy of the human TCR repertoire.
Our results provide insight into the heterogeneous immunobiology of PDAC, a presumed poorly immunogenic and checkpoint blockade-refractory tumour, demonstrating that neoantigens may be T-cell targets in LTSs. We propose that neoantigen quality, and not merely quantity, modulates immunogenicity, clonal fitness, and immunoselection during tumour evolution, with neoantigens in immun ogenic residues such as MUC16 emerging as apparent hotspots. Our data suggest that neoantigen-specific immunity gained during primary tumour outgrowth could be associated with decreased relapse and prolonged survival, comparable to classical mouse studies of prior tumour exposure protecting against tumour rechallenge 20 . Our findings support the development of strategies to harness neoantigen-specific immunity to treat checkpoint blockade-refractory cancers, and the identification of immunogenic hotspots for directed neoantigen targeting.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Data reporting.
No statistical methods were used to predetermine sample size. The investigators were not blinded to allocation during experiments and outcome assessment. Patient samples. MSKCC PDAC cohort. All tissues were collected at MSKCC following study protocol approval by the MSKCC Institutional Review Board. Informed consent was obtained for all patients. The study was in strict compliance with all institutional ethical regulations. All tumour samples were surgically resected primary pancreatic ductal adenocarcinomas. Patients treated with neoadjuvant therapy were excluded. All tumours were subjected to pathological re-review and histological confirmation by two expert PDAC pathologists before analysis. LTSs were defined as patients with overall survival of > 3 years from surgery, shortterm survivors as patients with survival > 3 months and < 1 year from surgery, to exclude perioperative mortalities. ICGC cohort. Clinical characteristics of the ICGC cohort have been described previously . Informed consent was obtained from all subjects. This program was deemed in accordance with the Health Insurance Portability and Accountability Act and the study protocol was approved by the Johns Hopkins Hospital Institutional Review Board. The study was in strict compliance with all institutional ethical regulations. Tissue microarray. Tissue microarrays were constructed from tumour and adjacent non-tumour cores from formalin-fixed, paraffin-embedded tissue blocks in short-(n = 45 tumours, 5 normal tissue) and long-term (n = 51 tumours, 5 normal tissue) survivors of PDAC. Histology sections were reviewed by two expert PDAC pathologists and the most representative areas were selected and marked on haematoxylin and eosin slides. 1 mm diameter cores were sampled from three different tumour regions per patient using an automated TMA Grand Master (Perkin Elmer). 5-μ m sections were prepared from tissue microarray blocks for immunohistochemistry. Patient subsets were randomly selected to undergo tissue microarray construction. Immunohistochemistry. Human-specific antibodies to MUC16 (clone OCT125, dilution 1:130), WT1 (clone CAN-R9 (IHC)-56-2, dilution 1:30), and annexin A2 (ab54771, 5 μ g ml −1 ) were purchased from Abcam. Antibodies to MUC1 (clone M695, dilution 1:100), and mesothelin (clone 5B2, dilution 1:50) were purchased from Vector Laboratories. Immunohistochemistry was performed using standard techniques. MUC16 expression was scored as described 23 . For each core, a cumulative MUC16 expression score was calculated as the product of a score for the frequency of tumour cells expressing MUC16 (0-25% = 1; 26-50% = 2; 51-75% = 3; 76-100% = 4) and a score for the intensity of staining (0 = negative; 1 = weak; 2 = moderate; and 3 = strong). The median expression score across triplicate cores is reported as the final score for each patient.
Multiplexed consecutive immunohistochemistry on the same slide was performed as described 3 . Tissue microarray slides were incubated overnight at 37 °C. Then, paraffin was removed using xylene and the tissue rehydrated before incubation in antigen-retrieval solution at 95 °C for 45 min (pH 9 Target Retrieval Solution, Dako). After endogenous peroxidase inhibition and FcR blocking, granzyme B was stained with anti-granzyme B monoclonal antibody (clone GrB-7, Dako) for 1 h at room temperature. After signal amplification with a horseradish peroxidase (HRP)-labelled polymer (Dako), the revelation was performed using 3-amino-9-ethylcarbazole (AEC, Vector Laboratories). Then slides were immersed in haematoxylin, rinsed in distilled water and mounted in aqueous-based mounting medium (Glycergel, Dako). After imaging using a whole-slide scanner, the slides were subjected to the Multiplexed Immunohistochemical Consecutive Staining ) for 5 h, followed by 60 min incubation with biotinylated goat anti-rabbit IgG (Vector Laboratories, PK6101) at 1:200 dilution. The detection was performed with streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems), followed by incubation with tyramide Alexa Fluor 488 (Invitrogen, T20922) prepared according to the manufacturer's instructions with predetermined dilutions. Next, slides were incubated with anti-FoxP3 (Abcam, ab20034, 5 μ g ml −1 ) for 4 h, followed by a 60 min incubation with biotinylated horse anti-mouse IgG (Vector Labs, MKB-22258) at 1:200 dilution. The detection was performed with streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems), followed by incubation with tyramide Alexa Fluor 568 (Invitrogen, T20914) prepared according to the manufacturer's instructions with predetermined dilutions. Finally, sections were incubated with anti-CK19 (Abcam, ab52625, 1 μ g ml −1 ) for 5 h, followed by a 60 min incubation with biotinylated goat anti-rabbit IgG (Vector, PK6101) at 1:200 dilution. The detection was performed with streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems), followed by incubation with tyramide Alexa Fluor 647 (Invitrogen, T20936) prepared according to the manufacturer's instructions with predetermined dilutions. After staining, slides were counterstained with 4′ ,6-diamidino-2-phenylindole (DAPI, Sigma Aldrich, D9542, 5 μ g ml −1 ) for 10 min and coverslips mounted with Mowiol.
For CD3, CD8 and CK19 staining, slides were first incubated with anti-CD3 (DAKO, A0452, 1.2 μ g ml
) for 4 h, followed by a 60 min incubation with biotinylated goat anti-rabbit IgG (Vector Labs, PK6101) at 1:200 dilution. The detection was performed with streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems), followed by incubation with tyramide Alexa Fluor 488 (Invitrogen, T20922) prepared according to the manufacturer's instructions with predetermined dilutions. Next, slides were incubated with anti-CD8 (Ventana, 790-4460, 0.35 μ g ml −1 ) for 5 h, followed by a 60 min incubation with biotinylated goat anti-rabbit IgG (Vector, PK6101) at 1:200 dilution. The detection was performed with streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems), followed by incubation with tyramide Alexa Fluor 568 (Invitrogen, T20914) prepared according to the manufacturer's instructions with predetermined dilutions. Finally, sections were incubated with anti-CK19 (Abcam, ab52625, 1 μ g ml −1 ) for 5 h, followed by 60 min incubation with biotinylated goat antirabbit IgG (Vector, PK6101) at 1:200 dilution. The detection was performed with streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems), followed by incubation with tyramide Alexa Fluor 647 (Invitrogen, T20936) prepared according to the manufacturer's instructions with predetermined dilutions. After staining, slides were counterstained with DAPI (Sigma Aldrich, D9542, 5 μ g ml ) for 10 min and coverslips mounted with Mowiol. Digital image processing and analysis. Tissue microarrays for each immunohistochemical stain were individually digitally scanned using Pannoramic Flash (3DHistech) with a 40× /0.95 numerical aperture (NA) objective. Image registration and alignment was performed using ImageJ (NIH). Regions of interest were drawn for each core and then transferred to others using CaseViewer (3DHistech). Each region from each scan was exported as a TIF file at full resolution (0.243 μ m per pixel). Images of the same core from multiple scans were stacked together and aligned using Linear Stack Alignment with SIFT algorithm from FIJI/ImageJ (NIH). Once aligned, the RGB images were colour deconvoluted to separate AEC and haematoxylin stainings and converted into eight-bit pseudo-fluorescent images. Individual immunohistochemical targets were sequentially assigned to fluorescent channels and subsequently merged. Haematoxylin staining was used to segment and count the number of nucleated cells in the core. After processing the images using background subtraction and median filter, staining was thresholded and split using Biovoxxel Watershed Irregular Features plugin. Regions of interest were drawn around each cell and matched to the signals from all other AEC stainings to count the number of positive cells for each staining. Total tissue area was measured by setting a very low threshold for haematoxylin images. For quantification, all nucleated cells were identified, followed by an intensity-based threshold determination of each target to identify positive cells. Triplicate cores were quantified followed by determination of the median number of cells per square millimetre of tissue (ImageJ, NIH). Quantification of cells detected using immunofluorescence was performed in a similar fashion. CD8
+ T cells were defined as CD3 + cells. Nucleic acid extraction. MSKCC PDAC cohort. 10 μ m slides were cut from OCTembedded frozen tumour and matched normal tissues. Sections were brought to containers with 70% ethanol for OCT removal. After OCT removal, specimens were dissected for subsequent DNA and RNA extraction. For whole-exome sequencing, tumour islands of > 70% cellularity were macrodissected based on expert PDAC pathological review, and DNA was extracted using the DNeasy kit. Total RNA from fresh frozen OCT-embedded tissues was extracted using TRIzol RNA Isolation Reagents (15596-026, Life Technologies). Rapid autopsy cohort. Genomic DNA was extracted using standard phenol-chloroform extraction followed by precipitation in ethanol. Quantification was achieved by LINE assay. Tissue samples confirmed to be of high quality and sufficient concentration were used for subsequent whole-exome sequencing. Transcriptome analysis. Extracted RNA was qualified on an Agilent BioAnalyzer and quantified by fluorometry (Ribogreen). Preparation of RNA for whole Letter reSeArCH transcriptome expression analysis was done using the WT Pico Reagent Kit (Affymetrix). Reverse transcription was initiated at the poly-A tail as well as throughout the entire length of RNA to capture both coding and multiple forms of non-coding RNA. RNA amplification was achieved using low-cycle PCR followed by linear amplification using T7 in vitro transcription technology. The cRNA was then converted to biotinylated sense-strand DNA hybridization targets. The prepared target was hybridized to GeneChip Human Transcriptome Array 2.0 (Affymetrix). Wash and scan was performed using the GeneChip Hybridization, Wash and Stain Kit using a Fluidics Station 450/250. Arrays were scanned using the GeneChip Scanner 3000. Data analysis for the array was done using Affymetrix Expression Console Software (SST-RMA algorithm to summarize the signal from array probesets). A dendritic cell signature was defined as described previously, using the genes CCL13, CCL17, CCL22, PPFIBP2, NPR1, HSD11B1, and CD209 (also known as DC-SIGN) 4 . Patient subsets were randomly selected to undergo transcriptomic profiling. TCR Vβ sequencing. Frozen tumour (short term n = 30, long term n = 30) and paired non-tumour adjacent pancreas tissue (short term n = 30, long term n = 30) samples were processed (Adaptive Biotechnologies). Genomic DNA was extracted according to the manufacturer's instructions (QIAsymphony, Qiagen). The quantity and quality of extracted DNA was verified before sequencing. Using a standard quantity of input DNA, the TCR Vβ CDR3 regions were amplified and sequenced using the survey multiplexed PCR ImmunoSeq assay. The ImmunoSeq platform combines multiplex PCR with high-throughput sequencing to selectively amplify the rearranged complementarity-determining region 3 (CDR3) of the TCR, producing fragments sufficiently long to identify the VDJ region spanning each unique CDR3. 45 forward primers specific for TCR Vβ gene segments and 13 reverse primers specific to TCR Jβ gene segments were used (Adaptive Biotechnologies). Read lengths of 156 bp were obtained using the Illumina HiSeq System. The ImmunoSeq assay allows for quantitative assessment of both total and unique TCRs in a sample, as it uses a complete synthetic repertoire of TCRs to establish an amplification baseline and adjust the assay chemistry to correct for primer bias. Barcoded, spiked-in synthetic templates were also used to measure and correct for sequencing coverage and residual PCR bias. Output data were then filtered and clustered using the relative frequency ratio between similar clones and a modified nearest-neighbour algorithm, to merge closely related sequences and remove PCR and sequencing errors. The number of rearranged TCRs per diploid genome in the input material (total number of T cells) was estimated as described previously 24 . The frequency of T cells was determined as the total number of T cells per total number of sequenced cells in the input material. A T-cell clone was defined as a T cell with a unique TCR Vβ CDR3 amino acid sequence. Clonality was defined as (1 − normalized entropy). Normalized entropy was calculated as the Shannon entropy divided by the logarithm of the number of unique productive (exonic) TCR sequences. Shannon entropy equals the clonal abundance of all productive TCR sequences in the input material. For in vitro stimulated cells, clones with identical amino acid sequences that expanded > 2-fold on day 21 compared to day 0, and fulfilled the Fisher's exact test and Storey's Q value for false discovery rate were defined as expanded. Data analysis was performed using Adaptive Biotechnologies ImmunoSeq Analyzer (Analyzer 3.0). Whole-exome sequencing. For all MSKCC PDAC patients, 500 ng of genomic DNA was fragmented to a target size of 150-200 bp on the Covaris LE220 system. Barcoded libraries (Kapa Biosystems) were subjected to exon capture by hybridization using the SureSelect Human All Exon 51MB V4 kit (Agilent). DNA libraries were subsequently sequenced on a HiSeq 4000 (Illumina) in a Paired End 100/100, using the TruSeq SBS Kit v3 (Illumina) with a target coverage of 150× for tumour samples and 70× for matched normal (MSKCC Center for Molecular Oncology). Sequence data were demultiplexed using CASAVA, and after removal of adaptor sequences using cutadapt (v1.6), reads were aligned to the reference human genome (hg19) using the Burrows-Wheeler Alignment tool (bwa mem v0.7.12). Duplicate-read removal, InDel realignment and base quality score recalibration were performed using the Genome Analysis Toolkit (GATK) according to GATK best practices, as described previously 6 . Variants were identified on processed data using Mutect, Mutect rescue (SNPs) and HaplotypeCaller (insertions/ deletions). A mean unique sequence coverage of 167.45× was achieved for tumour samples and 84.75 for normal samples. All MUC16 mutations were manually reviewed by 3 investigators using the Integrated Genomics Viewer v2.3.72. Whole-genome and whole-exome sequencing for ICGC 21 patients has been described previously. For all ICGC and rapid autopsy samples, BAM files were re-processed and mutations identified as per the above outlined MSKCC protocol. Depth of sequencing for the rapid autopsy samples ranged from 150× to 250× . HLA typing. HLA typing for patients with PDAC was performed in silico using the tool Short Oligonucleotide Analysis Package (SOAP)-HLA (http://soap.genomics. org.cn/SOAP-HLA.html).
Somatic mutation immunogenicity predictions. MSKCC pipeline.
Immunogenicity of somatic mutations was estimated using a previously described bioinformatics tool called NASeek 6 . In brief, NASeek is a computational algorithm that first translates all mutations in exomes to strings of 17 amino acids, for both the wild-type and mutated sequences, with the amino acid resulting from the mutation centrally situated. Second, it evaluates putative MHC class I binding for both wild-type and mutant nonamers using a sliding window method using NetMHC3.4 (http://www.cbs.dtu.dk/services/NetMHC/) for patient-specific HLA types, to generate predicted binding affinities for both peptides. NASeek finally assesses for similarity between nonamers that were predicted to be presented by patient-specific MHC class I. All mutations with binding scores below 500 nM are defined as neoantigens (Supplementary Table 1 ). As the MSKCC pipeline was, on average, more stringent with respect to the number of neoantigens identified (in comparison to the pVAC-Seq pipeline below), all neoantigen predictions were performed with the MSKCC pipeline unless otherwise specified. pVAC-Seq pipeline. As an independent algorithm to identify neoantigens, we used the pVAC-Seq pipeline 7 with the NetMHCpan binding strength predictor (< 500 nM binding strength). As recommended, we used the variant effect predictor from Ensembl 25 to annotate variants for downstream processing by pVAC-Seq. Neoantigen fitness modelling. The fitness of a clone is defined as
where N α is the effective population size of tumour clone α and F α is the fitness of clone α . We assume that the fitness effects due to the immune system are separable from other tumour fitness effects; that is, = +
, where α F I denotes the contribution to fitness due to selection on neoantigens and α F 0 denotes contributions from other factors, such as classical tumour driver mutations. Our model assumes the two components are separable, which is essentially equivalent to assuming that targeting of neoantigens is emanating largely from passenger mutations. We test the hypothesis that, owing to T-cell-mediated immune recognition, for some tumours, the deleterious effects of immune pressure due to mutationderived neoantigens can become a dominant fitness effect, either counteracting or substantially slowing the growth rate of the tumour.
In general, the predicted effective total tumour population size at time τ, denoted as n(τ), is 
We rank samples according to the value of n(τ), on the basis of their neoantigenimmune interactions only. This is equivalent to the assumption that τ e F0 also does not vary as considerably across samples when compared with τ , and the deleterious effects of neoantigen recognition sufficiently counterbalance the growth of the tumour. By ranking tumours according to n(τ), we therefore test whether tumours with the strongest deleterious effects owing to neoantigen fitness have better survival.
For a given neoantigen with sequence s we calculate R as the probability that neoantigen s is recognizable by the T-cell receptor repertoire. We do so by calculating the probability that a neoantigen sufficiently aligns to an epitope e from the IEDB via a thermodynamic model using the alignment score between the two peptides, | s, e| :
IEDB
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where a represents the horizontal displacement of the binding curve and k sets the slope of the curve at a. The partition function then becomes
The set of known positive epitopes were derived from the IEDB, restricting the search to all human infectious disease, class I-restricted targets with positive immune assays (http://www.iedb.org/). As the peptides in IEDB can change over time, the version of IEDB used in our study is included (Supplementary Table 2 ). The alignments between all neoantigens and IEDB epitope sequences are found with the blastp algorithm using BLOSUM62 matrix (gap opening penalty = − 11, gap extension penalty = − 1). For the identified alignments the alignment scores are then computed with Biopython Bio.pairwise2 package (http://biopython.org).
The amplitude due to relative MHC dissociation constants between a neoantigen and its wild-type counterpart is
MT , approximated here by the ratio of their inferred MHC binding affinities, which are inferred for neoantigens and their wild-type counterpart using NetMHC3.4 (http://www.cbs.dtu.dk/ services/NetMHC/) as described above. We use the standard cutoff for K d MT , the mutant dissociation constant, used in the literature, that is
. For a given neoantigen, the quantity A × R is referred to as the recognition potential of a neoantigen, and is a measure of neoantigen quality in regard to T-cell receptor recognition. Fitness due to T-cell-mediated neoantigen recognition within a clone is defined as
where i is an index running over neoantigens within a clone; that is, within a clone α, the maximal product of the amplitude A i and the recognition probability R i for a neoantigen. As an alternative hypothesis, fitness in the neoantigen load hypo thesis
where L α is the simple number of neoantigens in clone α. For all cases, we computed the neoantigen load without clonal phylogeny, which was the standard benchmark, and the neoantigen load with clonal phylo geny, by taking into account the effective size of clones in which neoantigens were contained. We also compared our results to those obtained using the wild-type recognition potential alone-in which case our MHC amplitude was 1-and the fitness model without clonality, which essentially just scores the best neoantigen across the tumour.
We split samples by the median value of the cohort, with samples below this value designated as a low fitness group (neoantigen quality high group), and those above as a high fitness group (neoantigen quality low group). We then compared survival for high-versus low-quality groups, expecting high-quality tumours to be related to longer patient survival times. Our model has three parameters: a, k and τ. We observe significant separation of patients at a sufficiently steep probability binding function; we therefore set the slope parameter k = 1. We report values for the shift and time parameters, a and τ, which optimized survival, as quantified by the log-rank test score using the lifelines software package (https://lifelines. readthedocs.io/en/latest/). To test the stability of this choice, we derived the optimal value for subsampled datasets, with subsampling frequencies of 0.5, 0.7, and 0.9. The optimal parameters obtained on the full dataset, a = 26 and τ ∈ . . [0 02, 0 04] were the most frequent choice for all subsampling frequencies (as shown on the distribution of optimal parameters in Extended Data Fig. 7a) .
We repeated the same analysis on the larger ICGC cohort with 166 patients. The optimal parameters obtained on the full dataset were a = 23 and τ ∈ . . [0 19, 0 21]; however the optimum depended only marginally on τ, raising significant patient segregation for a very broad interval of values (in particular at τ ∈ .
. [0 02, 0 04], optimal for the MSKCC cohort, we obtain P < 0.01, see Extended Data Fig. 7a) . We observe that the horizontal displacement parameter a is lower than in the MSKCC cohort. We attribute this trend to the difference in the survival time distribution in the two cohorts and the MSKCC cohort containing extreme LTSs, with probably 'higher quality' neoantigens. In vitro T-cell assays. Fresh blood was collected from seven PDAC LTSs whose tumours were identified on the basis of whole-exome sequencing and in silico predictions to harbour neoantigens. PBMCs were isolated by density centrifugation over Ficoll-Paque Plus (GE Healthcare). Peptides were generated for immunodominant neoantigens as predicted by the neoantigen quality algorithm (the neoantigen with the maximum quality score within a tumour, driven by maximal TCR recognition probability was defined as the immunodominant neoantigen), MUC16 neoantigens, and the corresponding wild-type nonamers (Peptide 2.0, Supplementary Table 2 ). In vitro peptide stimulation was performed as described with minor modifications 6 . In brief, 1 × 10 6 PBMCs were cultured with mutant or wild-type peptides (10 μ g ml −1 ) on day 1. IL-2 (50 U ml ) were added on day 2 and every subsequent 2-3 days. Mutant and wild-type peptides were added to respective cultures on day 7, and day 14 for second and third rounds of restimulation. On day 21, cells were restimulated in the presence of peptide for 5 h and cells were subsequently stained as per the manufacturer's instructions or subject to sequencing. A peptide pool of 23 class-I-restricted viral peptides from human cytomegalovirus and influenza virus (CEF, Cellular Technology Limited) served as a positive control (data not shown). Normalized expansion on day 21 of culture was defined as (absolute CD8 ) and β -actin-HRP antibody (Sigma Aldrich). Transfected cells were also analysed by immunocytochemistry (clone 4H11). Statistics. Comparisons between two groups were performed using an unpaired two-tailed Mann-Whitney U-test (unpaired samples), a paired two-tailed MannWhitney U-test (paired samples), and a two-tailed Student's t-test (normally distributed parameters). Multiple samples were compared using a Kruskal-Wallis test (non-grouped) and ANOVA with Tukey's post-test for multiple comparisons (grouped). Survival curves were compared using a log-rank test (Mantel-Cox). Categorical variables were compared using a χ 2 test. All comparison groups had equivalent variances. Specific clonal expansion on day 21 compared to day 0 (> 2-fold expansion by Fisher's exact test and Storey's Q value for false discovery rate) was assessed by TCR Vβ sequencing. In Fig. 3d , we tested whether the number of clones expanding under more than one condition (mutant, cross reactive, tumour) is significantly different than that which would be observed by chance using Poissonfamily saturated log-linear models with the canonical link function and the corresponding P values for the third-degree term in these models. We used a hypothetical value of 10 7 for the total number of clones in the blood for this calculation. The glm function in R version 3.4 was used for fitting these models. P < 0.05 was considered to be statistically significant. Data analysis was performed using statistical software (Prism 7.0, GraphPad software; Cox regression using STATA 13.1). Data availability. Data presented in this study can be downloaded from https:// dcc.icgc.org/repositories under the identifier PACA-AU. Transcriptomic data are available under Gene Expression Omnibus (GEO) accession number 89997. Source Data are provided for all experiments, including Figs 1b, c, e, 3a-d, 4a-e, and Extended Data Figs 2a-c, 3a, 3c, 3e, 4c, 6b, 8e, 9a-f, 10a . All other data are available from the corresponding author upon reasonable request. Code availability. The data (Supplementary Table 1) , the computational algorithm and software used, (Extended Data Fig. 7) , and the source code (Supplementary Data 1) allowing for reproduction of the neoantigen quality evaluation in this manuscript are included as indicated above. (one liver metastasis, one metastasis to small bowel/mesentery, one splenic metastasis). n is the number of biologically independent samples in individual patients. P values were determined using a log-rank test (a) and a two-sided Fisher's exact test (gender, tumour location, pN, pM, margin, chemotherapy), a two-sided χ 2 test (procedure, pathological stage, pT, adjuvant treatment) and an unpaired, two-tailed Student's t-test (age) (b-g).
Letter reSeArCH + and CD4 + cells in tumour tissue microarrays of short-and long-term survivors. Slides used were cut from separate sections of the block as those used for sequential immunohistochemistry (in a and Fig. 1b) . Bottom right: quantification of multiplexed immunophenotyping as shown in a (left and top right). All immunofluorescent and immunohistochemical staining was repeated independently in triplicate for each patient. In a, short term n = 45, long term n = 51. b, Bulk tumour transcriptomic immune profiling in shortand long-term survivors. Dendritic-cell signature genes include CCL13, CCL17, CCL22, PPFIBP2, NPR1, HSD11B1 and CD209 (also known as DC-SIGN) 3 . c, Flow-cytometric gating strategy to phenotype human T cells (n = 7). The first plot is pre-gated on live cells, followed by CD45 hi long-term pancreatic cancer survivors compared to all other patients (rest). n is the number of biologically independent samples in individual patients. P values were determined using a log-rank test (b, d) and a χ 2 test (e). n is the number of biologically independent samples in individual patients. P values were determined using a log-rank test (a, d). Figure 6 | Neoantigen quality is independently prognostic of survival. a, Top: overall survival of patients whose tumours displayed high compared to low neoantigen quality (neoantigen quality hi/low ) (left), and overall survival of patients who did or did not receive adjuvant chemotherapy (right). Bottom: overall survival of all four groups. Neoantigen quality defined by pipeline and schema as defined in Extended Data Fig. 5a , b. The table shows univariate and multivariate Cox regression analyses of the associations of clinicopathological features, adjuvant chemotherapy and neoantigen quality with overall survival. Data include all patients in the whole-exome sequencing MSKCC cohort. b, Number of nonsynonymous, missense and neoantigenic mutations per patient in the ICGC cohort (n = 166). c, Top: overall survival of patients in the ICGC cohort whose tumours displayed high compared to low neoantigen quality (neoantigen quality hi/low ) (left), and overall survival of patients in the ICGC cohort stratified by adjuvant chemotherapy administration (right). Bottom: overall survival of all four groups. Neoantigen quality defined by pipeline and schema as defined in Extended Data Fig. 5a , b. The table shows univariate and multivariate Cox regression analyses of the associations of clinicopathological features, adjuvant chemotherapy and neoantigen quality with overall survival in the ICGC cohort. Data on adjuvant chemotherapy is included for patients whose treatment status was available. n is the number of biologically independent samples in individual patients. P values were determined using a log-rank test (a, c). 90% of patients left, over 500 iterations of subsampling at each frequency. c, Overall survival of patients in the MSKCC and ICGC cohorts; whole tumours displayed high compared to low neoantigen quality (neoantigen quality hi/low ). Neoantigen quality was calculated using alignment to immunogenic infectious disease-derived IEDB peptides (microbial peptides) or using alignment to immunogenic non-infectious diseasederived allergy or autoimmune peptides in the IEDB database (nonmicrobial peptides). n is the number of biologically independent samples in individual patients. P values were determined using a log-rank test (c). 27 ) and the right blot with anti-β -actin. The red rectangle indicates the MUC16-specific band. All cells in the bottom panels were probed with anti-MUC16 antibody (clone 4H11 27 ). The inserted mutation was identical to a neoantigenic MUC16 mutation (detected in patient 1 shown in Extended Data Fig. 9a ). Data are representative of two independent experiments with similar results. c, MUC16 immunohistochemistry on samples from two long-term survivors of pancreatic cancer with MUC16 neoepitopes in primary resected tumours. Areas in rectangular low-power fields are shown magnified in the right panels. Immunohistochemical staining was performed independently in triplicate for each patient in tissue microarrays, and confirmed with immunohistochemical staining on whole tumour sections (shown). Horizontal bars indicate median values, error bars represent the s.e.m. n is the number of biologically independent samples in individual patients. P values were determined using a twotailed Student's t-test (a).
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to the investigator with respect to the short and long term cohorts.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
For statistical measurements in Figure 3D , the glm function in R version 3.4 was used for model fitting these models.
All data analysis was performed using Prism 7.0, GraphPad Software unless otherwise indicated.
Cox regression was performed using STATA 13.1.
Mutations were called using Mutect (https://software.broadinstitute.org/gatk/ download/mutect), Mutect Rescue (https://github.com/soccin/BICvariants_pipeline/tree/master/rescue), and HaplotypeCaller (https:// software.broadinstitute.org/gatk/documentation/tooldocs/current/ org_broadinstitute_gatk_tools_walkers_haplotypecaller_HaplotypeCaller.php_.
Neoantigens were called using NASeek (reference # 9), and pVAC_Seq (https:// github.com/griffithlab/pVAC-Seq).
MHC amplitude calculations were performed using NetMHC 3.4 (http:// www.cbs.dtu.dk/services/NetMHC-3.4).
TCR recognition probability was calculated using blastp Biopairwise 2 (https:// github.com/biopython/biopython.github.io/).
Tumor clonal structure was calculated using PhyloWGS. (https://github.com/ morrislab/phylowgs) For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
All clinicopathologic and population characteristics of all human research participants are provided in detail in Extended Data Tables 1-6 . Briefly, all patients had surgically resected primary pancreatic ductal adenocarcinomas. Patients treated with neoadjuvant therapy were excluded. All tumors were subjected to pathologic re-review and histologic confirmation by two expert PDAC pathologists prior to analyses. Long term survivors were defined as patients with overall survival > 3 years from surgery, short term survivors as patients with survival >3m and < 1 year from surgery to exclude perioperative mortalities. Patients were not excluded based on age or gender. For patients included in the Rapid Autopsy cohort, primary and metastatic tumor samples were collected posthumously from four patients as part of the Gastrointestinal Cancer Rapid Medical Donation program. Informed consent was obtained from all subjects.
